Login to Your Account

In The Clinic NEWS

All four doses of fasinumab, a nerve growth factor therapy under development at Regeneron Pharmaceuticals Inc., helped 338 patients with moderate-to-severe osteoarthritis pain in their hip or knee.

About the 5 percent drop in overall response rate in the expanded phase I trial with the company’s ADC for ovarian cancer, Immunogen Inc.’s chief development officer, Charles Morris, said he was “not sure I’d call it significant.”

Positive data with Oncosec Medical Inc.'s Immunopulse interleukin-12 electroporation therapy against melanoma "set pulses racing," in the words of H.C. Wainwright analyst Mark Breidenbach.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: